ESMO24 symposium on the management of oligoprogressive disease – Dana-Farber’s Breast Oncology Center

Dana-Farber’s Breast Oncology Center shared a post on X:

”Don’t miss special ESMO24 symposium on the management of oligoprogressive disease where Nancy Lin will discuss CNS disease.

Date: Monday, September 16.
Time: 5:05 – 15:20 pm CEST (9:05 am EST).
Location: Granada Auditorium – Hall 6.”

Source: Dana-Farber’s Breast Oncology Center/X

Dana-Farber Cancer Institute, located in Boston, Massachusetts, is a leading institution for cancer treatment and research. It was founded by Sidney Farber on 1947. Currently, the Institute has over 5,000 staff, faculty, and clinicians on board. They manage in excess of 640,000 outpatient visits each year, oversee more than 1,000 hospital discharges annually, and are actively involved in over 1,100 ongoing clinical trials.

As of 2023, Dana-Farber is ranked as the #4 cancer hospital globally. Dana-Farber’s research contributions include the development of Gleevec, a highly successful treatment for chronic myeloid leukemia.

Nancy Lin, an American oncologist, serves at the Dana-Farber Cancer Institute and holds the position of Associate Professor of Medicine at Harvard Medical School. Focused on HER2 positive breast cancer, her research explores novel diagnostic methods and treatment modalities. Recognized for her contributions, she received the Breast Cancer Research Foundation Westchester Women’s Award in Memory of Marla Mehlman in 2007. Dr. Lin leads multiple clinical trials, advocating for targeted therapies in metastatic breast cancer patients.